#3472 PRELIMINARY DATA FROM MOTHER HDX STUDY: A MULTICENTRE OPEN-LABEL RCT STUDY TO EXPLORE THE MORBIMORTALITY WITH THE THERANOVA HDX VS OL-HDF

Abstract Background and Aims Dialysis patients have a high rate of cardiovascular morbidity mortality. For this reason, new technical advances are necessary to be introduced in clinical practice. Medium cut-off (MCO) membranes generation that allow the removal greater number medium-sized molecules compared high-flux hemodialysis (HF-HD) but retaining albumin. Theranova, MCO membrane has an increased permeability also produces convective volume form internal filtration. these special properties, generated concept therapy called expanded HD (HDx). Until now, online hemodiafiltration (OL-HDF) demonstrated its superiority, terms survival, HF-HD. But comparison between OL-HDF HDx is question not solved. Method The MOTheR study trial (NCT03714386) open-label, multicentric, prospective, 1:1 randomized, parallel-group designed evaluate efficacy safety incident Spain for up 36 months. main endpoint determinate if non inferior at reducing combined outcome all-cause dead stroke (ischemic or hemorrhagic), acute coronary syndrome (angina myocardial infarction), peripheral arterial disease (amputation revascularization) ischemic colitis (mesenteric thrombosis). Results Now we enrolled 513 patients, 44 excluded 469 were randomized. 229 allocated 240 OL-HDF. No differences found neither baseline characteristics, pharmacological treatment, nor laboratory parameters. Follow time was similar both groups: 15.06 (12.8) vs 13.73 (11.51) months [HR 0.84 (0.50-1.40)] without mortality: 29 (12.7%) 31 (12.9%) 0.89 (0.54-1.48)] HDF respectively (Figure 1). Conclusion These preliminary results from Mother support mortality outcome.